MeSH D007898 - visceral leishmaniasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Amphotericin b | Amphotericin B | 1995-03-31 | |||
| Hospira | Pentamidine isethionate | Pentamidine Isethionate | 1992-06-30 | |||
| Bristol Myers Squibb | Amphotericin b | Fungizone | 1982-01-01 | |||
| Sun Pharmaceuticals | Amphotericin b | Amphotericin B | 2021-12-14 | |||
| Astellas Pharma | Amphotericin b | Ambisome | 1997-08-11 | |||
| Abbott Biotherapeutics | Amphotericin b | Amphotericin B | 1996-12-23 | |||
| GE Healthcare | Meglumine, Metrizoic acid | Isopaque | 1982-01-01 | |||
| Knight Therapeutics | Miltefosine | Impavido | 2014-03-19 | |||
| Leadiant Biosciences | Amphotericin b | Abelcet | 1995-11-20 | |||
| Eugia Pharma Specialties | Amphotericin b | Amphotericin B | 2022-11-17 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
67%2/3
Phase 3
92%11/12
Approved: 5Overall Success rate: 61%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use